Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer

▤ Summary

Takeda Pharmaceutical says the US FDA has approved rusfertide for a rare blood cancer. The approval expands treatment options for patients with this condition. The news centers on a life sciences company and a new therapy reaching the market. It does not describe software, but it is relevant to an audience tracking pharma companies and their commercial activity.

▦ Linked Companies